GUNN & Co INVESTMENT MANAGEMENT INC. Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

GUNN & Co INVESTMENT MANAGEMENT INC. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1,194.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 237,273 shares of the company’s stock after buying an additional 218,949 shares during the quarter. Johnson & Johnson comprises about 2.5% of GUNN & Co INVESTMENT MANAGEMENT INC.’s portfolio, making the stock its 18th largest holding. GUNN & Co INVESTMENT MANAGEMENT INC.’s holdings in Johnson & Johnson were worth $37,190,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Raymond James & Associates grew its holdings in Johnson & Johnson by 0.4% during the fourth quarter. Raymond James & Associates now owns 6,061,707 shares of the company’s stock worth $950,112,000 after acquiring an additional 26,982 shares during the period. Ninety One UK Ltd grew its stake in shares of Johnson & Johnson by 0.3% during the 4th quarter. Ninety One UK Ltd now owns 4,436,013 shares of the company’s stock worth $695,301,000 after purchasing an additional 12,867 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in shares of Johnson & Johnson by 4.8% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 4,396,416 shares of the company’s stock valued at $688,198,000 after purchasing an additional 200,193 shares during the period. Stifel Financial Corp boosted its holdings in Johnson & Johnson by 2.9% during the third quarter. Stifel Financial Corp now owns 4,306,268 shares of the company’s stock worth $670,726,000 after buying an additional 120,891 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its position in Johnson & Johnson by 22.2% during the third quarter. Envestnet Asset Management Inc. now owns 3,957,429 shares of the company’s stock worth $616,370,000 after buying an additional 719,472 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

Shares of Johnson & Johnson stock opened at $149.85 on Friday. The firm has a market cap of $360.64 billion, a PE ratio of 9.34, a P/E/G ratio of 2.46 and a beta of 0.55. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The business’s fifty day moving average is $153.45 and its two-hundred day moving average is $154.93.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period last year, the company earned $2.68 EPS. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. Royal Bank of Canada decreased their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Monday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.